Reuters logo
4 个月前
BRIEF-Genentech says FDA advisory committee unanimously recommends approval of co’s subcutaneous rituximab for certain blood cancers
2017年3月29日 / 下午4点25分 / 4 个月前

BRIEF-Genentech says FDA advisory committee unanimously recommends approval of co’s subcutaneous rituximab for certain blood cancers

1 分钟阅读

March 29 (Reuters) - Genentech:

* FDA advisory committee unanimously recommends approval of Genentech's subcutaneous rituximab for certain blood cancers

* FDA is expected to make a decision on approval for rituximab by June 26, 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below